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Abstract
Background: Clinical Bioinformatics is currently growing and is based on the integration of clinical and omics data
aiming at the development of personalized medicine. Thus the introduction of novel technologies able to investigate
the relationship among clinical states and biological machineries may help the development of this ﬁeld. For instance
the Aﬀymetrix DMET platform (drug metabolism enzymes and transporters) is able to study the relationship among
the variation of the genome of patients and drug metabolism, detecting SNPs (Single Nucleotide Polymorphism) on
genes related to drug metabolism. This may allow for instance to ﬁnd genetic variants in patients which present
diﬀerent drug responses, in pharmacogenomics and clinical studies. Despite this, there is currently a lack in the
development of open-source algorithms and tools for the analysis of DMET data. Existing software tools for DMET data
generally allow only the preprocessing of binary data (e.g. the DMET-Console provided by Aﬀymetrix) and simple data
analysis operations, but do not allow to test the association of the presence of SNPs with the response to drugs.
Results: We developed DMET-Analyzer a tool for the automatic association analysis among the variation of the
patient genomes and the clinical conditions of patients, i.e. the diﬀerent response to drugs. The proposed system
allows: (i) to automatize the workﬂow of analysis of DMET-SNP data avoiding the use of multiple tools; (ii) the
automatic annotation of DMET-SNP data and the search in existing databases of SNPs (e.g. dbSNP), (iii) the association
of SNP with pathway through the search in PharmaGKB, a major knowledge base for pharmacogenomic studies.
DMET-Analyzer has a simple graphical user interface that allows users (doctors/biologists) to upload and analyse
DMET ﬁles produced by Aﬀymetrix DMET-Console in an interactive way. The eﬀectiveness and easy use of DMET
Analyzer is demonstrated through diﬀerent case studies regarding the analysis of clinical datasets produced in the
University Hospital of Catanzaro, Italy.
Conclusion: DMET Analyzer is a novel tool able to automatically analyse data produced by the DMET-platform in
case-control association studies. Using such tool user may avoid wasting time in the manual execution of multiple
statistical tests avoiding possible errors and reducing the amount of time needed for a whole experiment. Moreover
annotations and the direct link to external databases may increase the biological knowledge extracted. The system is
freely available for academic purposes at: https://sourceforge.net/projects/dmetanalyzer/ﬁles/
Background
Nowadays the tight collaboration among molecular biol-
ogists, medical doctors and computer scientists resulted
in the development of novel research areas in which they
share their experiences and know-how. Thus the classi-
cal bioinformatics ﬁeld devoted to the investigation of
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biological data has moved towards the clinical scenario
[1,2].
A main research direction of this area is represented
by the possibility to integrate biological and clinical data,
e.g. through the integration of omics data into Electronic
Patient Records. The combined use of genomics, pro-
teomics, and clinical data may thus improve healthcare
management allowing the development of novel thera-
pies that are customised to the patients on the basis of
their own characteristics. The rationale is that the exhaus-
tive comprehension of biological systems may enable
© 2012 Guzzi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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the development of the so-called personalized medicine,
because the response to a treatment is determined by the
characteristics of the genome of each individual [3]. This
may enable the development of therapies and drugs that
are targeted to a speciﬁc patient improving the eﬀective-
ness of drugs themselves [4,5].
The recent introduction of new technologies, such as
the Aﬀymetrix SNP 5.0, SNP 6.0, and DMET (www.
aﬀymetrix.com) and the Illumina Genotyping (www.
Illumina.com), have enabled the high-throughput analysis
of the genomes of patients. As a consequence large-scale
studies of genetic variations in human are made possi-
ble at a relatively moderate costs yielding a big impact in
the Translational Medicine. In a clinical scenario such a
possibility has enabled the design of studies aiming at the
identiﬁcation of the genomic variants that may correlate
with diﬀerent classes of phenotypes, such as diseases, or
response to drugs, e.g.in pharmacogenomics experiments
[6-9].
Each individual has a unique sequence of DNA that
determines his/her characteristics. Diﬀerences can be
measured in terms of substitutions of bases in the same
position. Research focused particularly in the substitution
of a single base that occurs in a small subset of the popula-
tion. Thesemutations, also referred to as single nucleotide
polymorphisms (SNP’s), are usually deﬁned as a stable
substitution of a single base with a frequency of more
than 1% in at least one population. Let us consider the
short sequences ATGT and ACGT, a base change occurs
at position 2 and is denoted by “T/C” [10,11].
Many works have demonstrated a correlation between
the presence of SNPs and the development of diseases,
and more recently the eﬀectiveness of drugs [12,13]. Thus
the presence (or the absence) of speciﬁc SNPsmay be used
as a clinical marker for the prediction of drug eﬀective-
ness, foreseeing the response of individuals with diﬀerent
SNPs to drugs.
Such sub-ﬁeld of genomics, also known as pharma-
cogenomics, concerns the study of variations in genes
responsible for the metabolism of drugs. Moreover, phar-
macogenomics also focuses on the investigation of adverse
drug reactions (ADR) that occur most frequently when
a drug has a narrow therapeutic index. The therapeutic
index is a measure of the amount of drug that may cause
lethal eﬀect. When a drug has a narrow therapeutic index,
this means that there exists little diﬀerence between the
lethal and the therapeutic dose.
Pharmacogenomics experiments (as deeply discussed in
next Section), involve the selection of a candidate cohort
of population, the gene sequencing and the individuation
of SNPs by using microarray technology and computa-
tional analysis. The DMET (drug metabolism enzymes
and transporters) Plus Premier Pack is a novel microar-
ray assay developed by Aﬀymetrixa designed speciﬁcally
to test drug metabolism associations [14] in pharmacoge-
nomics case-control study.
DMET is able to genotypize function variants in a
deﬁned set that comprises 225 ADME-related genes, i.e.
genes known to be related to drug absorption, distribu-
tion,metabolism and excretion (ADME) [15-17]. Diﬀerent
recent works demonstrated the roles of genetic variations
in ADME genes in association with the heterogeneity in
drug treatment eﬀects. For instance, Li et al. [15] demon-
strated in a systematic way that polymorphisms in ADME
genes are correlated to the diﬀerence in drug responses.
In that work authors systematically tested ADME genes,
then analyzed the polimorphisms demonstrating the asso-
ciation with response to drugs.
In two works of Di Martino et al. [18,19], the DMET
platform has been used to evidentiate polimorphisms
related to toxicity of drugs in two diﬀerent cancer
types. The workﬂow of these works is the same: data
produced by DMET platform are manually mined by
scientists. The use of DMET-Analyzer, as explained
in following section, may automatize the analysis of
these data, resulting in obtaining the same results in
less time.
Data produced by DMET platform must be prepro-
cessed and analyzed in order to ﬁnd correlation between
the presence/absence of SNPs and the status of sam-
ples (e.g. type of drug treatment). To the best of our
knowledge, existing software tools, e.g. the DMET Con-
sole platform, generally allow only the preprocessing of
binary data and simple data analysis operations, but do
not allow to test the association of the presence of SNPs
with the response to drugs. Consequently, researches have
to export and manually process SNPs tables produced
by the DMET Console. The discovery of statistically sig-
niﬁcant associations requires the use of external tools
(e.g. statistical softwares) and the manual execution of
multiple tests.
An association study represents an exciting application
scenario for clinical bioinformatics [20]. In fact there is
the need for introducing both methodologies and soft-
ware tools supporting all the phases of the experiments.
During the design phase, accurate studies have to deter-
mine both the right population size and the sampling
strategies avoiding: (i) that ﬁnal results may be biased of
either the sampling strategy or the sample size, (ii) that
money is wasted by the eﬀectuation of meaningless
experiments.
In this paper we present DMET-Analyzer, a tool for
the automatic statistics test of the association between
SNPs and examined sample conditions. DMET Ana-
lyzer is a platform-independent software built in Java
that supports the statistical analysis of DMET data. It
has a simple graphical user interface that allows users
to upload and analyse DMET ﬁles produced by DMET
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Console in an interactive way. Considering the usual
workﬂow of a pharmacogenomics experiment, the pro-
posed tool receives as input DMET data produced by
the Aﬀymetrix platform and produces as output a list of
candidate SNPs together with their biological and phar-
macogenomics interpretations as stored in main public
databases.
DMET Case Control Data Analysis workﬂow
A typical workﬂow of a case-control association study
performed by using the DMET platform. involves the
following steps, as depicted in Figure 1:
• Sample collection and DMET chip preparation: in
this phase biological samples are collected and treated
to perform microarray experiments; the Aﬀymetrix
DMET chip allows the investigation of 1936 diﬀerent
nucleotides that present possible variants as stored in
SNP databases, each one representing a portion of
the genome having a role in drug metabolism;
• DMETmicroarray experiments, this phase
produces ﬁrst raw microarray data (.CEL data);
• DMET data preprocessing: raw data (.CEL)
produced by the instrument are further preprocessed
by the DMET console software that produces as
output single preprocessed ﬁles (.CHP) for each
sample or the whole dataset representing all the
samples (usually tabular data); the DMET Console
software produces a table containing, for each
nucleotide and for each sample, the detected SNP or
a NoCall value (where NoCall means that the
platform has not revealed the nucleotide with a
suﬃcient conﬁdence).
• SNPs detection:, this phase statistically analyses SNP
data producing as output knowledge models (e.g. a
binary classiﬁer built on top of the SNP distribution
among classes) or statistical models that help to ﬁnd
signiﬁcant SNPs. The selection of the statistical test
span over a broad range, from simple Fisher’s tests
that analyse the signiﬁcance of a single SNP to
complex tests that analyse those of a set of SNPs.
Implementation
DMET-Analyzer tool supports the visualization of the
SNPs detected on the entire dataset as a heatmap to
give an immediate visual feedback to the user. It imple-
ments a Hardy-Weinberg equilibrium calculator that can
be used for testing the genetic model. It is able to auto-
matically read the class assigned to each sample (patient)
that can be provided in the header row of the DMET
dataset. Finally, it annotates signiﬁcant SNPs with infor-
mation provided by Aﬀymetrix libraries and with links to
the dbSNP database (for basic information about SNPs)
and to the PharmaGKB pharmacogenomics knowledge
base, giving various information (e.g. pathways) related to
pharmacogemomics.
DMET Analyzer: a tool for DMET Data Analysis
In this section we describe main functions of DMET Ana-
lyzer. The tool sits in the middle of a typical workﬂow
of an association-study experiment aiming at the identi-
ﬁcation of the discriminative SNPs among two classes as
depicted, in Figure 1, and consequently main functions of
our software are:
Loading and Visualization of Data produced by
DMET console: DMET Analyzer currently is able to
parse information encoded as excel data ﬁles as well
as tab delimited ﬁles. User in this way may also
prepare his/her own dataset, e.g. merging together
samples coming from diﬀerent experimental batches.
The structure of the input ﬁle is described in Table 1.
The software is able to ﬁnd the class-labels directly
from the input ﬁles. For instance, the classes may be
healthy-diseased or the kind of response to drugs, e.g.
toxicity or not-toxicity. It is possible to visualize the
SNP distribution of the dataset in order to enable a
fast analysis of data themselves.
Analysis of Variants: DMET Analyzer automatically
selects the relevant SNPs. The current version of
DMET Analyzer veriﬁes, for each SNP, the
association among the presence of SNP and the
classes yet determined through the use of the well
known Fisher’s test. Fisher’s test has been chosen
because literature contains examples of
pharmacogenomics studies containing few samples
(less than 20) so this test represents a good choice
[21].
Moreover, two multiple test corrections are available
(Bonferroni and False Discovery Rate) in order to
improve the statistical signiﬁcance of results. For
each SNP it is possible to analyse the linkage
disequilibrium by using a Hardy-Weinberg calculator
embedded into DMET-Analyzer.
The current version of DMET-Analyzer contains a
simple implementation of the Pearson’s chi-square
test to calculate the deviation from the
Hardy-Weinberg equilibrium for bi-allelic probesets.
The calculator is manual, so the user has to insert the
observed allele frequencies for the Homozygote
reference, the Homozygote variant and the
Heterozygote, and the signiﬁcance level of the test.
The calculator will estimate the deviation from the
equilibrium and will test the hypothesis that such
deviation is signiﬁcant.
Annotation of Data: Finally, for each SNP it is
possible to access both annotations provided by
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Figure 1Workﬂow of a clinical bioinformatics experiment from the sample collection to the data analysis.Workﬂow of data in a typical
experiment.
Aﬀymetrix and the dbSNP [22] to explain the
biological ﬁnding of results.
Pharmacogenomics Interpretation: For each
analyzed SNP, it is possible to obtain additional
information stored in the Pharmacogenomics
Knowledge Base [23]. It is also possible to obtain
additional information about the analyzed SNPs and
their clinical interpretation associated with drug
response, as well as drug dosing guidelines,
drug-centered pathways, and relationships among
genes, drugs and diseases.
DMET Analyzer Implementation
DMET Analyzer is a platform-independent application
and it is entirely implemented using the Java programming
languageb.
DMET Analyzer User Interface
DMET Analyzer provides a simple Graphical User Inter-
face allowing the user an easy access to the tool func-
tionalities. After launching the software, a simple user
interface enables the user to load data ﬁles into the
system. After that the loading is completed, data are
arranged automatically in tabular form and samples
are automatically assigned to classes speciﬁed on the
input ﬁles.
Now it is possible to begin the analysis step starting the
execution of all statistical tests. In order to avoid wasting
time on the calculation of meaningless tests, DMET Ana-
lyzer employs an optional optimization step that enable
the calculation of Fisher’s tests only for probes whose
SNPs distributions presents a diﬀerence greater than a
threshold. It should be noted that we also oﬀer the pos-
sibility to calculate all the tests without this optimization
step, even if the optimization step has not introduced bias
nor eliminated useful SNPs.
Moreover, user can specify a subset of rows to test.
Results and discussion
Algorithm of analysis in DMET Analyzer
This section presents the analysis algorithm implemented
into DMET Analyzer. The algorithm takes as input a data
Table 1 DMET data format
Probes Subject1 Subject2 Subject3 Subject4
Probe1 C/C C/C T/T T/T
Probe2 G/C C/C -/T A/A
Probe3 C/T C/T C/T C/T
Proben G/G A/G G/G G/G
In this table is represented a possible Example of input table, produced at the end of DMET-Console workﬂow. Where each row represents a probe identiﬁed by its
own identiﬁer, and each column represents a subject represented by its own identiﬁer. File must contain in the ﬁrst row a list of speciﬁc identiﬁers: the probe set
identiﬁers in the ﬁrst column and the identiﬁers of subjects, in the subsequent ones. The cell ( i,j) contains the allele belonging at i-th subject into the j-th probe set,
identiﬁed in the previous analysis.
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matrix representing the detected SNPs for each patient
and the classes to which a patient belongs to. Table 1
represents an example of such data. The analysis algo-
rithm iteratively considers each row and analyses the
frequency distribution of each SNP. For each symbol a
Fisher’s test is performed and statistically signiﬁcant dif-
ferences among classes are reported. Let us consider, for
instance, Table 1 that represents a compact example of
data produced by DMET console. First row represents
the names of the samples while ﬁrst column contains
the identiﬁer of SNPs. A generic element (i, j) contains the
i − th identiﬁed SNP in the j − th sample, so it has the
form X/Y , where X,Y ∈ {A,T ,C,G,−}. Now let us sup-
pose, without loss of generality, that the ﬁrst two columns
belong to class A while the remaining ones belong to
class B. It is evident that distribution of Probe1 is clearly
diﬀerent among two classes. The analysis algorithm iter-
atively and automatically test such diﬀerences for each
SNP. The output of such an algorithm is a list of SNPs
candidates and the related p-values whose distribution is
diﬀerent among classes. Such information need to be fur-
ther tested or validated through integration with other
biological information or with other wet lab experiments.
For each SNP the annotations provided by Aﬀymetrix are
also available and, for further investigations, the system
allows the automatic search into the dbSNP database or
the PharmaGKB.
Analysis of data in DMET-Analyzer
As proof-of-principle we tested the ability of DMET Ana-
lyzer to ﬁnd statistically relevant SNPs on real data and
for evaluating the performances we used some synthetic
datasets. We built some synthetic datasets containing
the same number of probes as real DMET data and an
increasing number of samples grouped in two classes.
We populated these data with randomly distributions of
SNPs and signiﬁcantly diﬀerent distributions of SNPs.
Tests revealed the ability of DMET Analyzer to recognize
statistically diﬀerent SNPs, from the other ones. These
datasets are available for test on the DMET Analyzer
web site.
In order to process data using DMET Analyzer user has
to load data into the software. Data can be stored as a
textual ﬁle or in a Excel data ﬁle (in this example we use
an Excel data ﬁle). After that the loading has been com-
pleted DMET Analyzer shows the data table to the user
as depicted in Figure 2(a) (ﬁrst row contains the sam-
ple identiﬁers, ﬁrst column contains the probe identiﬁers
where each cell contain the identiﬁed alleles). User has to
attribute the right class to each sample (Figure 2-b). At
this point user can start the preprocessing by selecting
the proper function in the upper menu. Actually DMET
Analyzer oﬀers the calculation of the exact Fisher’s-test
for all the alleles or for a speciﬁed set of alleles and three
possible method for calculating the p-value (no correc-
tion, Bonferroni Corrected and FDR). In both cases user
has to select the two classes of the dataset and the p-value
calculationmethod as depicted in Figure 2(c). At this point
DMET Analyzer calculates the Fisher’s-tests, and ﬁnally
it shows the results in a new window in which probes
may be sorted alphabetically or by p-value as depicted in
Figure 2(d). User can select a SNP in this table and may
visualize annotation data by just clicking on the SNP iden-
tiﬁer as depicted in Figure 2(e). Software oﬀers both the
annotations provided by Aﬀymetrix and a link to external
databases (dbSNP in the current version). DMET Ana-
lyzer also provides a compact visualization of data as
depicted in Figure 2(g).
Scalability and benchmark
Here we show the eﬀectiveness of our approach show-
ing the computation times, the memory occupancy and
the scalability for a growing number of patients. It should
be noted that our approach is based on the calculation
of Fisher test for each SNP, then the performance are
related to the number of computed tests and are indepen-
dent from the number of patients. Figure 3 shows how
the execution times for a growing number of patients
from 100 to 1000 (typical numbers in genomics stud-
ies) are substantially unvaried while the memory occu-
pancy remains almost unaﬀected by the high number
of patients. Experiments are conducted on a Mac OS X
10.7.2, equipped with an Intel Core 2 Duo 2.2 Ghz pro-
cessor, 4Gb of RAM memory and Java (TM) SE Runtime
Environment.
Analysis of real DMET Data
The eﬀectiveness of the DMET Analyzer approach has
been tested by the Bioinformatics Laboratory and the
Tommaso Campanella Cancer Center [24,25]. In partic-
ular here we demonstrate as proof of concept the ability
of DMET Analyzer to ﬁnd the same results as those pub-
lished in two works of Di Martino et al. [18,19], hereafter
Case Study 1, and Case Study 2. In both works we took
part in the data analysis performing the statistical tests in
a manual way without the use of DMET Analyzer. Finally,
we performed the analysis using our software, producing
in a very smaller time the same results as those published
in [18,19].
In Case Study 1 [18], a cohort of 19 patients aﬀected by
multiple myeloma (MM) treated with aminobisphospho-
nate zoledronic acid (ZA) were enrolled in a case-control
study. In particular nine patients presented osteonecro-
sis (ONJ) after the treatment and ten patients were the
control ones.The study protocol was approved by our
University Hospital Bioethical Committee and informed
consent was obtained from each patient. The aim of the
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Figure 2Workﬂow of an experiment of analysis through the software. Figure shows the workﬂow of execution of a typical analysis. Initially
user loads data into the software as depicted in the upper left corner of Figure 2(a). Then user has to attribute the right class to each sample
(Figure 2 b) and to choose the analysis method Figure 2(c). The software calculates the allele frequencies for each allele and for each probe. At this
point DMET Analyzer calculates the Fisher’s-tests and ﬁnally it shows the results in a new window in which probes may be sorted alphabetically or
by p-value as depicted in Figure 2(d). User can select a SNP in this table and may visualize annotation data by just clicking on the SNP identiﬁer as
depicted in Figure 2(e). Analogously, user may visualize the distribution of variants using the embedded visualizer as evidenced in Figure 2(f).
study was to investigate the association among speciﬁc
SNPs and the adverse event ONJ induced by ZA. Results
demonstrated the presence of eight SNPs that were related
to ONJ. We obtained data from the local University Hos-
pital after the deletion of personal identiﬁer in compliance
with the Italian law. Then we identiﬁed eight SNPs that
were statistically associated with ONJ occurrence. We
individuated a statistical diﬀerence among the distribu-
tion of SNPs: rs1152003, rs10893, rs4725373, rs1049793,
rs2463437, rs903247, rs2468110, and rs2097937 (the same
SNPs with same p-values were previously identiﬁed in the
reference work).
In Case Study 2 [19] a cohort of twenty six patients
was used to investigate the genomic basis of the
irinotecan-induced gastrointestinal (GI) toxicity by
the novel drug-metabolizing enzyme and transporter
(DMET) microarray genotyping platform. Patients who
had undergone irinotecan-based chemotherapy enrolled
experiencing a grade 3 gastrointestinal (GI) toxicity,
control - matched patients without GI toxicity - study.
We obtained data from the local university hospital after
the deletion of personal identiﬁer in compliance with the
Italian law. We used DMET Analyzer to mine this data
and we identiﬁed 3 SNPs mapping in ABCG1, ABCC5
and OATP1B1/SLCO1B1 transporter genes associated
with GI toxicity: The homozygous genotype C/C in the
ABCC5 gene (P=0.0022). The homozygous genotype G/G
in the ABCG1 (P=0.0135) and the heterozygous genotype
G/A in the OATP1B1/SLCO1B1 gene (P=0.0215). Results
obtained using DMET Analyzer were the same as those in
published work.
In conclusion, we were able to obtain the same results
as published but performing in an automatic way the
workﬂow of Figure 1 in a fraction of the time, and avoid-
ing possible errors due to the manual investigation and
processing of data.
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Figure 3Memory Occupancy and Execution Times. Figure shows the execution time and the total amount of requested memory for a growing
dimension of dataset. We performed these measures for diﬀerent datasets considering ten datasets from 100 to 1000 patients increased by 100.
Results show that the implementation of DMET Analyzer and the algorithmic choice enable the processing of this dataset requesting approximately
the same time and the same memory for the execution (except for the initial loading of ﬁles).
RelatedWork
The DMET platform has been recently introduced by
Aﬀymetrix, so there is a lack of methodologies of anal-
ysis and related tools. For the purposes of this work we
discuss brieﬂy the Aﬀymetrix proprietary tools and we
report some preliminary work of analysis. To the best of
our knowledge, there is not a single tool able to implement
all the steps of the workﬂow of analysis, especially for
case-control association studies. Recent works discussing
the use of such data, in fact, do not indicate a speciﬁc
software for the statistical analysis but reuse existing plat-
forms and speciﬁc procedures for translating the DMET
datasets into a readable format [14,26]. In the rest of the
section we brieﬂy present a comparison of our software
with respect to the state of the art tools. The compari-
son is made on the basis of a typical workﬂow of analysis
and aims to evidence the functionalities of our tool and
possible future improvements. Since our tool focuses on
DMET data analysis, in the following we present a com-
parison with main tools for such analysis. Moreover in
the Additional ﬁle 1 the interested reader may ﬁnd a
broader and deeper comparison with general tools for
SNP analysis.
Comparisonwith existing Tools
Comparison with apt-dmet-genotype apt-dmet-
genotypea is a command-line software provided
by Aﬀymetrix that supports probe-set summariza-
tion of binary .CEL ﬁles, the management of resulting
preprocessed ﬁles (.CHP). Considering the whole
workﬂow of analysis described in this paper, the
apt-dmet-genotype perform the ﬁrst step, as
depicted in Figure 4. It does not build the ﬁnal tabular
dataset containing the genotype call for all the probesets
and all the samples. User consequently has to use the
DMET Console to perform such phase. Compared to
Guzzi et al. BMC Bioinformatics 2012, 13:258 Page 8 of 10
http://www.biomedcentral.com/1471-2105/13/258
Figure 4 Comparison with existing Tools. Comparison of DMET Analyzer with respect to existing software tools considering a typical workﬂow of
analysis. Data produced by the DMET platform may be preprocessed using apt-dmet-genotype. Then this data may be given as input to
DMET-Console to be transformed into a format readable by other softwares. Diversely DMET console may perform these two steps. Then this data
may be processed by statistical tools after some manual steps. Conversely our software is able to perform automatically all ﬁnal steps.
DMET Analyzer, apt-dmet-genotype presents some
main diﬀerences:
• it lacks in the possibility of doing statistical analysis;
• it is not extensible for the preprocessing of
multivendor or user deﬁned datasets;
• it does not produce data that may be directly analysed.
On the other hand, the current version of DMET Ana-
lyzer lacks in the management of Aﬀymetrix binary ﬁles.
The adding of such functionalities may constitute the plan
for future development of DMET Analyzer.
Comparison with DMET Console DMET-Consolea is a
GUI-based software provided by Aﬀymetrix that supports
probe-set summarization of binary .CEL ﬁles, the man-
agement of resulting preprocessed ﬁles (.CHP) and ﬁnally
the building of a tabular dataset containing the genotype
call for all the probesets and all the samples. It includes
both genotypization and quality control algorithms as well
as the possibility to make other analysis such as Copy
Number Variations controls. Compared to DMET Ana-
lyzer, the Aﬀymetrix Expression Console presents some
main diﬀerences:
• it lacks in the possibility of doing statistical analysis
• it is not extensible for the preprocessing of
multivendor or user deﬁned datasets;
On the other hand, the current version of DMET Ana-
lyzer lacks in quality control capabilities compared to
DMET Console and in the possibility to manage directly
Aﬀymetrix binary ﬁles. Thus DMET-Console can be seen
as a main datasource for our software.
Conclusions
There exists an increasing interest in the scientiﬁc and
medical community for the study of the impact of drugs
on single patients and for the development of speciﬁc
drugs for each patient. The rationale of this interest is
based on the consideration that the response to the drugs
is strictly related to the genomic diﬀerences, so the elu-
cidation of these diﬀerences and their impact to the
drug-response could unravel meaningful knowledge. Such
discipline, known as pharmacogenomics, is a relatively
novel ﬁeld that is based on a technological platform for the
investigation of the eﬀect of drugs on single patients look-
ing at their genomes. Although this is important, there is
a lack of comprehensive tools able to perform all the steps
of the workﬂow of analysis. In particular, while the pre-
processing can be performed using freely available tools
provided by the chip vendor, the subsequent analysis steps
require the adaptation of data to existing tools.
In this paper we presented DMET Analyzer, a soft-
ware platform for the analysis of such data able to read
and extract signiﬁcant SNP from Aﬀymetrix DMET data.
DMET Analyzer tool supports the visualization of the
SNPs detected on the entire dataset as a heatmap to
give an immediate visual feedback to the user. It imple-
ments a Hardy-Weinberg equilibrium calculator that can
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be used for testing the genetic model. It is able to auto-
matically read the class assigned to each sample (patient)
that can be provided in the header row of the DMET
dataset. Finally, it annotates signiﬁcant SNPs with infor-
mation provided by Aﬀymetrix libraries and with links to
the dbSNP database (for basic information about SNPs)
and to the PharmaGKB (Pharmacogenomics Knowledge
Base), giving various information (e.g. pathways) related
to pharmacogemomics. Additional ﬁle 2 presents a brief
user guide.
Availability and requirements
• Project name: DMET Analyzer
• Project home page: https://sourceforge.net/
projects/dmetanalyzer/ﬁles/.
• Operating system(s): DMET Analyzer tool is
available for Windows, Linux, and MacOSX
operating systems.
• Programming language: Java
• Other requirements: Java 1.6.1 Runtime or higher.
• License: GNU GPL.
• Any restrictions to use by non-academics: The





Additional ﬁle 1: Detailed Comparison among DMET Analyzer and
relatd softwares. The additional ﬁle provides a detailed comparison of
DMET-Analyzer with respect to related softwares.
Additional ﬁle 2: DMET-Analyzer Tutorial. File provides a quick and
easy guide to installation and use of DMET-Analyzer.
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